Article Text
Editorial commentary
Sequencing of and escalation paradigms for MS therapies: time for a rethink?
Statistics from Altmetric.com
Footnotes
Contributors Completely BVT’s own observations.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.